STUDY PROTOCOL

Stromal vascular fraction-enriched fat grafting as treatment of adherent scars: study design of a non-randomized early phase trial

Linda Vriend1,2, Joris A. van Dongen1,3, Anouk Pijpe4,5,6, Marianne K. Nieuwenhuis7,8,9, Sandra J. M. Jongen7, Martin C. Harmsen1, Paul P. M. van Zuijlen4,6,10 and Berend van der Lei2,11,12*

Abstract

Background: In the last decades, autologous fat grafting has been used to treat adherent dermal scars. The observed regenerative and scar-reducing properties have been mainly ascribed to the tissue-derived stromal vascular fraction (tSVF) in adipose tissue. Adipose tissue's components augment local angiogenesis and mitosis in resident tissue cells. Moreover, it promotes collagen remodeling. We hypothesize that tSVF potentiates fat grafting-based treatment of adherent scars. Therefore, this study aims to investigate the effect of tSVF-enriched fat grafting on scar pliability over a 12-month period.

Methods and design: A clinical multicenter non-randomized early phase trial will be conducted in two dedicated Dutch Burn Centers (Red Cross Hospital, Beverwijk, and Martini Hospital, Groningen). After informed consent, 46 patients (≥18 years) with adherent scars caused by burns, necrotic fasciitis, or degloving injury who have an indication for fat grafting will receive a sub-cicatricic tSVF-enriched fat graft. The primary outcome is the change in scar pliability measured by the Cutometer between pre- and 12 months post-grafting. Secondary outcomes are scar pliability (after 3 months), scar erythema, and melanin measured by the DSM II Colormeter; scar quality assessed by the patient and observer scales of the Patient and Observer Scar Assessment Scale (POSAS) 2.0; and histological analysis of scar biopsies (voluntary) and tSVF quality and composition. This study has been approved by the Dutch Central Committee for Clinical Research (CCMO), NL72094.000.20.

Conclusion: This study will test the clinical efficacy of tSVF-enriched fat grafting to treat dermal scars while the underlying working mechanism will be probed into too.

Trial registration: Dutch Trial Register NL 8461. Registered on 16 March 2020

Keywords: Adherent scars, Scar quality, Burn scars, Stromal vascular fraction, Adipose-derived stromal cells, ASC, Fat grafting, Pliability

Background

The first fat grafting procedure was described in 1893 to treat a soft tissue defect for reconstructive purposes [1]. Nowadays, fat grafting is routinely used for both reconstructive as well as esthetic purposes and is far “more than volume correction alone” [2, 3]. In 2001, Zuk et al. described the adipocyte stromal cells (ASCs) that are present in large amounts in the stromal vascular fraction

*Correspondence: b.van.der.lei@umcg.nl

1 Department of Plastic Surgery, University of Groningen and University Medical Center of Groningen, Groningen, the Netherlands

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
(SVF) of adipose tissue and possess multipotent capabilities [4]. This discovery led to an increased use of fat grafting for regenerative and scar-reducing purposes and to treat damaged tissues, such as burn wounds [5]. Since then, it is thought that observed beneficial effects are for a large part attributed to the SVF in adipose tissue.

SVF is easily obtained by dissociating liposaprate enzymatically or mechanically [6]. SVF comprises the non-adipocyte fraction of fat and is composed of stromal cells such as fibroblasts and other mesenchymal stromal cells as well as vasculature cells (endothelial and smooth muscle). The stromal cells produce and maintain the extracellular matrix that embeds and supports the cells in SVF. Recently, a reliable, fast, intraoperative mechanical isolation procedure has been developed to yield tissue-derived stromal vascular fraction (tSVF), which makes clinical application of tSVF more feasible than enzymatic isolated SVF (cellular SVF) [7–9]. On the one hand, tSVF probably effectuates better retention of paracrine factors through extracellular matrix components that lack in single cell suspensions like cSVF, where cells disappear through leakage of lymph vessels. On the other hand, tSVF is a unit of transplanted tissue that provides a nutritious environment, serving as a therapeutic component of adipose tissue. Case reports and retrospective studies have reported improved esthetic outcomes and pain relief after autologous fat grafting of problematic and adherent scars [3, 5, 10–23]. These results hold promise but, besides the obvious methodological drawbacks of the study design, lack adequate scar evaluation with validated objective or subjective scar measurement tools. Moreover, physical, physiological, and psychological evaluation and measurements are also important since adherent scars cause physical burden, e.g., stiffness and impaired range of motion, and psychological burden, e.g., psychosocial distress [24, 25]. Several validated scar scales, e.g., the Patient and Observer Scar Assessment Scale (POSAS), Vancouver Scar Scale (VSS), and Manchester Scar Scale (MSS), have been developed to assess the aforementioned aspects of scar quality [26–28]. The POSAS is recognized as a highly reliable scar rating scale; moreover, it also includes the patients’ opinion and is therefore favorable for subjective scar assessment ([29], www.posas.org).

Recently, autologous fat grafting was effectively used to improve scar quality, in particular scar pliability and pain in adherent scars [30]. Scar pliability and color were assessed with validated objective measures, i.e., the Cutometer and DSM II Colormeter, and scar quality and pain with validated subjective measures, i.e., the POSAS patient and observer scales ([29, 31–37], www.posas.org). The results of the beforenamed studies warrant further research with SVF or ASCs, because these components are deemed responsible for a large part of the observed ameliorating effects on scar features [3, 5, 10–23, 30]. Moreover, enrichment of fat grafts with SVF may induce even larger and longer lasting ameliorating effects on scar features than plain autologous fat.

A well-designed clinical trial investigating these potential effects of SVF-enriched fat grafting is warranted. The aim of this study is to assess the efficacy of tSVF-enriched fat grafting in patients with adherent scars using a comprehensive scar evaluation protocol. This study will also provide benchmark data on histological change of adherent scars after tSVF-enriched fat grafting.

**Methods, design, and outcome measures**

**Objectives**

The aim of this study is to assess the efficacy of tSVF-enriched fat grafting in patients with adherent scars. The primary outcome measure is the change in scar pliability as assessed with the Cutometer Skin Elasticity Meter Dual MPA 580 (Courage and Khazaka GmbH, Cologne, Germany) pre- and 12 months post-tSVF-enriched grafting. The secondary outcome measures are scar erythema and melanin index, as a proxy for color and pigmentation, measured by the DSM II Colormeter (Cortex Technology, Hadsund, Denmark); scar quality assessed by the patient and observer scales of the Patient and Observer Scar Assessment Scale (POSAS 2.0); and histological features of tSVF and scar biopsies.

**Protocol and registration**

This study was approved by the Dutch Central Committee for Clinical Research (CCMO) NL72094.000.20 and by the Institutional Review Boards of the participating hospitals (Red Cross Hospital, Beverwijk, and Martini Hospital, Groningen, the Netherlands). Methods of the study are specified in a protocol that is registered at the Dutch trial register (March 16, 2020, NL 8461) (https://www.trialregister.nl/trial/8461).

**Trial design**

The trial design is a non-randomized early phase inpatient, before-after trial on the effect of tSVF-enriched fat grafting on scar pliability in patients with adherent scars and who are treated in the Red Cross Hospital, Beverwijk, or the Martini Hospital, Groningen, the Netherlands (Fig. 1).

Other study designs were considered but were not feasible for several reasons. For example, splitting a scar in two areas (one side treated with SVF-enriched fat grafting, one with plain fat grafting as the control group) may potentially lead to shifting of treatments from one side to the other, leading to unreliable results. Moreover, the effect of tSVF-enriched fat grafting or plain fat grafting is largely dependent on the individual's scar and the variability of the scar tend to be large in patients with adherent scars.
grafting may not be limited to its own area; thus, the border between both may display a gradient effect. Treating two separate scars within one patient was also considered but would exclude patients that do not have two scars and scars may possibly be not comparable. Therefore, the non-randomized study design was chosen optimum to obtain reliable results.

**Participants**

Patients, aged \( \geq 18 \) years with adherent scars (\( \geq 12 \) months old) caused by burns, necrotic fasciitis, or degloving injury, visiting the outpatient clinic of one of the Burn Centers in Beverwijk or Groningen who have an indication for fat grafting are eligible for this trial. Exclusion criteria are previous scar treatment with fat grafting, skin melanoma in patients’ history, pregnant or lactating, BMI <18 (general exclusion criteria for fat grafting procedure), unlikely to comply with the requirements of the study protocol and follow-up, and insufficient knowledge of the Dutch language (Table 1). Patients are included after they received a confirmed understandable and neutral explanation of the study by a member of the research team and after signing informed consent following the guidelines of the CCMO.
Before surgery, one scar area will be selected and marked according to a standardized algorithm for objective data collection (Fig. 2) [30]. The maximum size of the scar area is limited by the maximum quantity of tSVF that can be obtained and a minimum length of 2 cm will apply. Each scar consists of five measurement points. The five points in the selected area will be subjected to all study outcomes.

**Surgical procedure**

Plastic surgeons, who have had uniform training in fat grafting procedures and are also additionally trained in Dutch burn care centers, will carry out the study procedures. The results of this study will be directly translated to real-world setting, because in clinics the procedures will be executed by a similar set of plastic surgeons with similar fat grafting skills. Under general anesthesia, lipoaspirate is harvested from the abdominal wall, flank, or thigh with fine harvesting cannulas. Out of 10 ml lipoaspirate, 1 ml of tSVF will be produced intraoperatively with the fractionation of adipose tissue (FAT) procedure, a fat dissociation procedure using a fractionator (Figs. 3 and 4) [38]. For preparing the tSVF-enriched fat graft, 10 ml lipoaspirate in a 10-ml Luer-Lock syringe will be centrifuged at 3000 rpm with a 9.5-cm radius fixed angle rotor for 2.5 min (Medi-lite, Thermo Fisher Scientific, Waltham, MA) at room

| Table 1 Inclusion and exclusion criteria |
|-----------------------------------------|
| **Inclusion criteria**                  | **Exclusion criteria**                                          |
| - Age ≥18 years                         | - Previous scar treatment with fat grafting in selected scar    |
| - Patient has an adherent scar (minimum scar age: 12 months) caused by burns, necrotic fasciitis, or degloving injury, for which fat grafting is indicated | - General exclusion criteria for fat grafting procedures: pregnancy, lactating, BMI < 18 kg/m² |
| - Competent adults                      | - Skin melanoma in patient’s history                             |
| - Patients seen by a plastic surgeon in Burn centers of the Red Cross Hospital, Beverwijk or Martini Hospital, Groningen, The Netherlands | - Unwillingness to commit to the study protocol and show up for all follow-up moments |
|                                         | - Insufficient proficiency in Dutch to the extent that clear communication is not possible |

![Fig. 2 Selected scar divided in 5 points according to a standardized algorithm](image)

**Scar selection**

Before surgery, one scar area will be selected and marked according to a standardized algorithm for objective data collection (Fig. 2) [30]. The maximum size of the scar area is limited by the maximum quantity of tSVF that can
temperature (Fig. 5). Thereafter, the upper oily layer will be drained from the top while the bottom layer will be drained by removing the lower cap of the syringe. Subsequently, in the syringe, 9.0 ml of fat graft will be left to which is added 1.0 ml of tSVF: two syringes, one with 9 ml of fat and one with 1 ml of tSVF, will be connected to a Luer-Lock and the contents will be mixed by gently pushing the content of one syringe into the other, this way yielding the tSVF-enriched fat. Small incisions at the border of the scar are created to perform adhesiolysis of the selected scar. Then, the tSVF-enriched fat (tenfold excess fat over tSVF) will be injected under the scar. This procedure is repeated until the entire scar area has reached fat grafting saturation (when enriched fat graft starts coming out of the incision holes). After fat saturation, the scar is covered and fixed with gausses. Practically, 50 ml of fat has to be harvested to yield 25 ml of fat and 2.5 ml tSVF, resulting in 27.5 ml tSVF-enriched fat graft.

Study outcomes
Primary outcome measure
Scar pliability
The primary outcome measure is the change in scar pliability as measured by the Cutometer Skin Elasticity Meter Dual MPA 580® (Courage and Khazaka GmbH, Cologne, Germany) pre- and 12 months post-tSVF-enriched fat grafting (Figs. 2 and 6). The Cutometer® is a validated, reliable instrument which measures viscoelasticity of the skin by analyzing its maximal extension after inducing negative pressure ([33–37], https://www.trialregister.nl/trial/8461).

Secondary outcome measures
All scar outcome measurements will be performed by two trained observers who work independently of each other to prevent confirmation bias.
**Scar mechanics**

Scar, retraction, elasticity, viscoelasticity, and maximum extension will be measured with the Cutometer Skin Elasticity Meter Dual MPA 580 ® (Courage and Khazaka GmbH, Cologne, Germany) pre-tSVF-enriched fat grafting and 3 and 12 months post-tSVF-enriched grafting (Figs. 2 and 6) [30]. Scar pliability will also be measured after 3 months post-tSVF-enriched fat grafting.

Healthy skin measurements will be conducted as described pre-, 3, and 12 months post-tSVF grafting on the contralateral side of the treated scar. Healthy skin measurements will serve as a reference (i.e., the optimum skin mechanics within that person).

**Scar color and pigmentation**

Scar color and pigmentation will be measured with the DSM II Colormeter ® (Cortex Technology, Hadsund, Denmark), a validated and reliable tool that calculates an erythema and melanin index as a proxy for color and pigmentation (Figs. 2 and 7). Measurements of the selected scar and adjacent normal skin will be performed pre-, 3, and 12 months post-tSVF-enriched grafting [30].

**Scar quality**

Scar quality will be assessed by the POSAS version 2.0 ([29], www.posas.org). The POSAS Patient and Observer scales are completed pre-, 3, and 12 months post-tSVF-enriched grafting (Figs. 2 and 8). All items of the POSAS 2.0 will be scored on a 10-point rating scale and added together to obtain a final score. Additionally, item-specific scores and the overall opinion of the scar will be scored (Fig. 8).

**Standardized photographs**

A standardized photograph will be taken from each scar within 24 h before treatment under the same light and camera conditions each time.

**Histological analyses**

For participants in our study, scar biopsies are optional. If patients consent to biopsies, histological features will be assessed by taking a 2-mm biopsy of the selected scar on a fixed position: 1 cm left from point 1 within 24 h before treatment and at 12 months post-tSVF-enriched grafting 1 cm right from point 1 (Fig. 2). The skin sample will be fixed with 2% PFA and paraffin embedded. From each patient, 0.5 ml of tSVF will be 2% paraformaldehyde (PFA) fixed. Fixed samples will be transported to the University and Medical Center Groningen for histological analysis. There, thin sections of paraffin-embedded scar biopsies and tSVF will be deparaffinized and stained with H&E, Picrosirius red (extracellular matrix collagen), CD68 (macrophage infiltration), perilipin A antibodies (presence of residual adipocytes), alpha-smooth muscle actin antibodies (smooth muscle cells and myofibroblasts), and von Willebrand Factor and/or CD31 (endothelial cells). Stained sections will be scanned and subjected to image densitometry for quantification.

**Baseline patient and scar characteristics**

Patients’ baseline characteristics will be extracted from patients’ medical records and consist of the following: age; sex; skin type (Fitzpatrick); scar characteristics, e.g., scar age, cause of the scar; and prior surgery of the selected scar other than fat grafting (exclusion criterion), e.g., split skin grafting.

**Sample size calculation**

The primary outcome is the difference in pliability measured by the Cutometer (parameter Ue) between pre- and 12 months post-tSVF-enriched fat grafting. The expected effect size is based on the results of the study by Jaspers et al. on the Coleman fat grafting technique [30]. In this
study, scar pliability improved by 22.5%. The mean pliability measure was 0.51. At least this effect is expected to be found in tSVF-enriched fat grafting as well. An additional positive effect of 20% of tSVF-enriched fat grafting (compared to the Coleman technique) is considered a clinically relevant improvement of treatment in this study. Therefore, a sample size calculation was made with an expected effect size of 0.45. With a required minimum of 80% power, a two-tailed test, and \( p < 0.05 \) considered statistically significant, the required sample size is 41 patients (G*Power 3 version 3.1.9.2). With an anticipated maximum dropout rate of 10% at 12 months, we will need to include 46 patients to compensate for dropout.

**Statistical analysis**

Comparisons will be made for all primary and secondary outcome metrics of the selected scar and adjacent normal skin across all follow-up moments, thus pre-, 3, and 12 months post-tSVF-enriched grafting, according to the established data collection protocol [30]. Analyses will be performed using SPSS Statistics, version 27.0 (IBM Corp., Armonk, NY), and Image J (NIH, Bethesda, MD) for histological examination of skin biopsies. If data is normally distributed, results will be presented as mean with standard deviation and the primary outcome will be analysed with the paired \( T \)-test. Furthermore, the repeated measures ANOVA will be performed to detect any overall differences between related means across all time points. If the repeated measures ANOVA is statistically significant, we will run appropriate post hoc tests to highlight exactly where differences occur. If data is not normally distributed, appropriate non-parametric analyses are performed. Data will be analyzed using SPSS, and for histological analysis, GraphPad Prism (version 8.4; GraphPad Software, Inc., La Jolla, USA) will be used. \( p \)-values < 0.05 will be considered statistically significant.

**Discussion**

The aim of this non-randomized intra-patient before-after early phase trial is to assess the efficacy of tSVF-enriched fat grafting on the pliability of adherent scars caused after burn injury or fasciitis necroticans or...
degloving injury. The potential therapeutic capability of tSVF in adherent scars will be measured by validated objective and subjective scar assessment tools.

This proposed non-randomized study design is part of a larger series of consecutive non-randomized trials with identical study design and standardized algorithm and outcome assessment scheme to allow for identical scar follow-up [30]. The only difference between these studies is the fat grafting technique. These series of studies aim to determine the optimal (fat grafting) treatment for patients with adherent scars. Through the same study design, core outcome set, and patient populations (same inclusion criteria), the efficacy of the various techniques can be systematically compared. Moreover, it will enable historical cohort comparison over time. In this type of cohort series, as compared to classical randomized controlled trials (RCTs), no limiting inclusion criteria are used which provides a better representation of the true patient population to our opinion (real-world evidence).

This is in contrast to RCTs in which study populations often only present a small part of the true population due to strict inclusion and exclusion criteria (e.g., exclusion of comorbidities). However, a limiting factor of this study is the lack of a direct comparison of two or more fat grafting techniques under the exact same circumstances as is the case in a RCT. Nonetheless, the real-world data setting that this study provides may result in evidence of the efficacy of tSVF-enriched fat grafting in scar treatment.

In this study, the chosen primary outcome parameter is scar pliability measured by the Cutometer. This scar pliability assessment is a reliable, non-invasive, and painless parameter to assess the therapeutic effects of fat grafting as scar remodeling treatment and the Cutometer is also one of the most researched validated measurement devices to assess tissue pliability and elasticity [39]. Apart from the assessment of objective scar tissue features, inclusion of subjective patient measurements in scar assessment is essential. Subjective scar features are assessed using the validated and world-wide used POSAS questionnaires [26]. Besides the standardized protocol and core outcome set, the power of our trial design is also the proposed combination of clinical and histological analysis of tSVF-treated scar samples. Together, they offer great potential to measure therapeutic efficacy in a real-world setting. This combination will also provide insight in the underlying mechanism of potential regenerative effects of tSVF on scar tissue, which may have direct implications for future research and clinical applications. Moreover, the long follow-up period will reassure that fat, and possibly also tSVF, has initiated regenerative processes and scars have had allowance to reverse to healthier dermal tissue so that this can be objectified with the data outcome set [40].

To ensure equal quality of treatment in the participating centers of this multicenter study and to minimize the effect of confounding factors, several standardization measures were applied. For example, specific durations have been set for procedural steps, e.g., 80 min for normal fat grafting procedures and 20 min for concentrating and injection of SVF-enriched fat grafts. Furthermore, all fat grafting procedures will be carried out according to the Coleman technique and centers will use the same fractionators to manufacture tSVF. Moreover, only plastic surgeons with significant experience with fat grafting procedures will perform the surgeries to ensure equal standard of care. Finally, uniform outcome measures were selected and measurements will be executed by the same trained observers on all follow-up moments (not plastic surgeons to prevent observer or confirmation bias). Patients of the participating Dutch Burn Centers possibly provide an accurate model for burn patients and patients with adherent scars in most high-income countries and the surgical procedure is easily replicable in other like clinical environments where fat grafting can be carried out. This may improve the generalizability of the studies’ conclusions. We believe that our non-randomized multicenter study design is sufficiently powerful to provide such potential evidence that may alter the standard of care. This has precedent, for instance in the non-randomized trial of Jaspers et al., after which fat grafting for adherent scars became insured healthcare in the Netherlands.

In summary, our non-randomized trial will contribute to further optimizing fat grafting treatments of patients with adherent scars and may potentially lead to better and more optimal treatment options for adherent scars than other fat grafting techniques.

**Trial status**

This study design is a summary with backgrounds and explanations of the CCMO-approved protocol (version 2.0, 27 August 2020 NL72094.000.20) and complies with the guideline of Good Clinical Practice (GCP). Inclusion opens at December 2021 and is expected to be completed in October 2024.

**Abbreviations**

ASC: Adipose-derived stromal cell; CCMO: National Dutch Ethical Committee; cSVF: Cellular stromal vascular fraction; FAT: Fractionation of adipose tissue; MSS: Manchester Scar Scale; POSAS: Patient and Observer Scar Assessment Scale; SVF: Stromal vascular fraction; tSVF: Tissue stromal vascular fraction; VSS: Vancouver Scar Scale.

**Acknowledgements**

We would like to thank the Netherlands Organisation for Health Research and Development (ZonMw) and the Dutch Burn Foundation for their financial contribution.
Authors' contributions
All authors contributed to the design of this study. LV and JAD drafted the manuscript. AP performed the sample size calculation and designed the statistical analysis. AP, MN, PPMZ, MCH, and BL assisted to draft this manuscript. All authors reviewed the manuscript, provided comments, and approved the final manuscript.

Funding
This study is partially funded by the Netherlands Organisation for Health Research and Development (ZonMw), project number: 427002011, and the Dutch Burn Foundation.

Availability of data and materials
Not applicable.

Declarations

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Pathology & Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 2. Department of Plastic Surgery, University of Groningen and University Medical Center of Groningen, Groningen, the Netherlands. 3. Department of Plastic Surgery, University of Utrecht, and University Medical Center Utrecht, Utrecht, the Netherlands. 4. Burn Center, Red Cross Hospital, Beverwijk, the Netherlands. 5. Association of Dutch Burn Centers, Red Cross Hospital, Beverwijk, the Netherlands. 6. Department of Plastic, Reconstructive and Hand Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, the Netherlands. 7. Association of Dutch Burn Centers, Martini Hospital, Groningen, the Netherlands. 8. Research Group Healthy Ageing, Allied Health Care and Nursing, Hanze University of Applied Sciences, Groningen, the Netherlands. 9. Department of Human Movement Sciences, University Medical Center Groningen, Groningen, the Netherlands. 10. Pediatric Surgical Centre, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Vrije Universiteit, Amsterdam, the Netherlands. 11. Bergman Clinics, Heerenveen, the Netherlands. 12. Bergman Clinics, Heerenveen, the Netherlands.

Received: 28 November 2021 Accepted: 5 July 2022

Published online: 19 July 2022

References
1. Neuber G. Fettransplantation. Chir Kongr Verhandl Deutsche Gesellschaft für Chir. 1893;22:66.
2. Coleman SR. Hand rejuvenation with structural fat grafting. Plast Reconstr Surg. 2002;110(7):1731–44 discussion 1745-1737.
3. Coleman SR. Structural fat grafting: more than a permanent filler. Plast Reconstr Surg. 2006;118(5 Suppl):108s–20s.
4. Klinger M, Marazzi M, Vigo D, Torre M. Fat injection for cases of severe burn outcomes: a new perspective of scar remodeling and reduction. Aesthet Plast Surg. 2008;32(3):465–9.
5. Zük PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211–28.
6. Aronowitz JA, Lockhart RA, Hakakian CS. Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue. Springer-Plus. 2015;4:713.
7. van Dongen JA, Stevens HP, Parvizi M, van der Lee B, Harmsen MC. The fractionation of adipose tissue procedure to obtain stromal vascular fractions for regenerative purposes. Wound Repair Regen. 2016;24(6):994–1003.
8. Bourn P, Bunnell BA, Castella L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15(6):641–8.
9. van Dongen JA, Tuin AJ, Spiekman M, Jansma J, van der Lee B, Harmsen MC. Comparison of intraoperative procedures for isolation of clinical grade stromal vascular fraction for regenerative purposes: a systematic review. J Tissue Eng Regen Med. 2018;12(1):e261–74. https://doi.org/10.1002/term.2407.
10. Negenborn VL, Groen JW, Smit JM, Niessen FB, Mullender MG. The use of autologous fat grafting for treatment of scar tissue and scar-related conditions: a systematic review. Plast Reconstr Surg. 2016;137(1):31e–43e.
11. Spiekman M, van Dongen JA, Willemsen JC, Hoppe DL, van der Lee B, Harmsen MC. The power of fat and its adipose-derived stromal cells: emerging concepts for fibrotic scar treatment. J Tissue Eng Regen Med. 2017;11(11):3220–3235. https://doi.org/10.1002/term.2213.
12. Balkin DM, Samra S, Steinbacher DM. Immediate fat grafting in primary cleft lip repair. J Plast Reconstr Aesthet Surg. 2014;67(12):1644–50.
13. Bollerö D, Pozza S, Gangemi ÉN, et al. Contrast-enhanced ultrasonography evaluation after autologous fat grafting in scar revision. G Chr. 2014;43(11-12):266–73.
14. Bruno A, Delli Santi G, Fasciani L, Cempanani M, Palombo M, Palombo P. Burn scar lipofilling: immunohistochemical and clinical outcomes. J Craniofac Surg. 2013;24(5):1806–14.
15. Gussantes E, Fontdevila J, Rodriguez G. Autologous fat grafting for correction of unaesthetic scars. Ann Plast Surg. 2012;69(5):550–4.
16. Maione L, Mermeo A, Pedretti L, et al. Autologous fat graft as treatment of post short stature surgery correction scars. Injury. 2014;45(Suppl 6):S126–32.
17. Mazzola IC, Cantarella G, Mazzola RF. Management of tracheostomy scar by autologous fat transplantation: a minimally invasive new approach. J Craniofac Surg. 2013;24(4):1361–4.
18. Pallua N, Barocini A, Alharbi Z, Stropms JP. Improvement of facial scar appearance and microcirculation by autologous lipofilling. J Plast Reconstr Aesthet Surg. 2014;67(8):1033–7.
19. Phulpin B, Gangloff P, Tran N, Bravetti P, Merlin JL, Dolivet G. Rehabilitation of irradiated head and neck tissues by autologous fat transplantation. Plast Reconstr Surg. 2009;123(4):1187–97.
20. Ribuffo D, Atzeni M, Guerra M, et al. Treatment of irradiated expanders: protective lipofilling allows immediate prosthetic breast reconstruction in the setting of postoperative radiotherapy. Aesthetic Plast Surg. 2013;37(6):1146–52.
21. Sardesai MG, Moore CC. Quantitative and qualitative dermal change with microfat grafting of facial scars. Otolaryngol Head Neck Surg. 2007;137(6):868–72.
22. Wang G, Ren Y, Cao W, Yang Y, Li S. Liposculpture and fat grafting for aesthetic correction of the gluteal concave deformity associated with multiple intragluteal injection of penicillin in childhood. Aesthetic Plast Surg. 2013;37(1):39–45.
23. Zellner EG, Pfaff MJ, Steinbacher DM. Fat grafting in primary cleft lip repair. Plast Reconstr Surg. 2015;135(5):1449–53.
24. Krakowski AC, Totri CR, Donelan MB, Shumaker PR. Scar management in the pediatric and adolescent populations. Pediatrics. 2016;137(2):e20142065.
25. Brown BC, Moss TP, McGrouther DA, Bayat A. Skin scar preconceptions must be challenged: importance of self-perception in skin scarring. J Plast Reconstr Aesthet Surg. 2014;67(10):1022–9.
26. Carrière ME, Kwa KAA, de Haas LEM, et al. Systematic review on the content of outcome measurement instruments on scar quality. Plast Reconstr Surg Glob Open. 2019;7(9):e2424. https://doi.org/10.1097/GOX.0000000000002424.
27. Brasuellaers N, Pinayesh A, Hoeksema H, Verbelum J, Blot S, Monstrely S. Burn scar assessment: a systematic review of objective scar assessment tools. Burns. 2010;36(8):1157–64.
28. Sullivan T, Smith J, Kermode J, Mclver F, Courtmanche DJ. Rating the burn scar. J Burn Care Rehabil. 1990;11(3):256–60.
29. van de Kar AL, Corion LU, Smeulders MJ, Draaijers LJ, van der Horst CM, van Zuijlen PP. Reliable and feasible evaluation of linear scars by the Patient and Observer Scar Assessment Scale. Plast Reconstr Surg. 2005;116:S14–22.
30. Jaspers ME, Brouwer KM, van Trier AJ, Groot ML, Middelkoop E, van Zuijlen PP. Effectiveness of autologous fat grafting in adherent scars: results
obtained by a comprehensive scar evaluation protocol. Plast Reconstr Surg. 2017;139(1):212–9.

31. Verhaegen PDHM, van der Wal MBA, Middelkoop E, van Zuijlen PPM. Objective scar assessment tools: a clinimetric appraisal. Plast Reconstr Surg. 2011;127(4):1561–70. https://doi.org/10.1097/prs.0b013e31820a641a.

32. Draaijers LJ, Tempelman FR, Botman YA, Kreis RW, Middelkoop E, van Zuijlen PP. Colour evaluation in scars: tristimulus colorimeter, narrow-band simple reflectance meter or subjective evaluation? Burns. 2004;30:103–7.

33. Draaijers JL, Botman YA, Tempelman FR, Kreis RW, Middelkoop E, van Zuijlen PP. Skin elasticity meter or subjective evaluation of scars: a reliability assessment. Burns. 2004;30:109–14.

34. Fong SS, Hung LK, Cheng JC. The cutometer and ultra-sonography in the assessment of postburn hypertrophic scar: a preliminary study. Burns. 1997;23(Suppl 1):S12–8.

35. Edger-Lacoursière Z, Nedelec B, Marois-Pagé E, de Oliveira A, Couture MA-A, Caliva V, et al. Systematic quantification of hypertrophic scar in adult burn survivors. Eur Burn J. 2021;28:88–95.

36. Nedelec B, Correa JA, Rachelska G, Armour A, LaSalle L. Quantitative measurement of hypertrophic scar: intrarater reliability and concurrent validity. J Burn Care Res. 2008;29(3):501–11. https://doi.org/10.1097/BCR.0b013e3181710881 PMID: 18388576.

37. Clarys P, Alevaert K, Lambrecht R, Barel AO. Skin color measurements: comparison between three instruments: the Chromameter(R), the DermaSpectrometer(R) and the Mexameter(R). Skin Res Technol. 2000;6:230–8.

38. Van Dongen JA, Gostelie OFE, Vonk LA, De Bruijn JJ, Van Der Lei B, Harmesen MC, et al. Fractionation of adipose tissue procedure with a disposable one-hole fractionator. Aesthet Surg J. 2020;40(4):NP194–201. https://doi.org/10.1093/asj/spaa023 PMID: 31402379.

39. van der Wal M, Bloemen M, Verhaegen P, Tuinebreijer W, de Vet H, van Zuijlen P, et al. Objective color measurements: clinimetric performance of three devices on normal skin and scar tissue. J Burn Care Res. 2013;34:e187–94.

40. Spiekman M, Francia DL, Mossel DM, Brouwer LA, Diercks GFH, Vermeulen KM, et al. Autologous lipofilling improves clinical outcome in patients with symptomatic dermal scars through induction of a pro-regenerative immune response. Aesthet Surg J. 2021. https://doi.org/10.1093/asj/sjab280.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.